Skip to main content
SpringerLink
Log in

Anxiety in Patients with Schizophrenia: Epidemiology and Management

  • Therapy in Practice
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Anxiety symptoms can occur in up to 65 % of patients with schizophrenia, and may reach the threshold for diagnosis of various comorbid anxiety disorders, including obsessive–compulsive disorder (OCD) and post-traumatic stress disorder (PTSD). We review the clinical presentation, diagnosis, neurobiology, and management of anxiety in patients with schizophrenia, with a particular focus on pharmacotherapy. The prevalence of any anxiety disorder (at syndrome level) in schizophrenia is estimated to be up to 38 %, with social anxiety disorder (SAD) being the most prevalent. Severity of positive symptoms may correlate with severity of anxiety symptoms, but anxiety can occur independently of psychotic symptoms. While anxiety may be associated with greater levels of insight, it is also associated with increased depression, suicidality, medical service utilization, and cognitive impairment. Patients with anxiety symptoms are more likely to have other internalizing symptoms as opposed to externalizing symptoms. Diagnosis of anxiety in schizophrenia may be challenging, with positive symptoms obscuring anxiety, lower levels of emotional expressivity and communication impeding diagnosis, and conflation with akathisia. Higher diagnostic yield may be achieved by assessment following the resolution of the acute phase of psychosis as well as by the use of screening questions and disorder-specific self-report instruments. In schizophrenia patients with anxiety, there is evidence of underactive fear circuitry during anxiety-provoking stimuli but increased autonomic responsivity and increased responsiveness to neutral stimuli. Recent findings implicate the serotonin transporter (SERT) genes, brain-derived neurotropic factor (BDNF) genes, and the serotonin 1a (5HT1a) receptor, but are preliminary and in need of replication. There are few randomized controlled trials (RCTs) of psychotherapy for anxiety symptoms or disorders in schizophrenia. For pharmacotherapy, data from a few randomized and open trials have shown that aripiprazole and risperidone may be efficacious for obsessive–compulsive and social anxiety symptoms, and quetiapine and olanzapine for generalized anxiety. Older agents such as trifluoperazine may also reduce comorbid anxiety symptoms. Alternative options include selective serotonin re-uptake inhibitor (SSRI) augmentation of antipsychotics, although evidence is based on a few randomized trials, small open trials, and case series, and caution is needed with regards to cytochrome P450 interactions and QTc interval prolongation. Buspirone and pregabalin augmentation may also be considered. Diagnosis and treatment of anxiety symptoms and disorders in schizophrenia is an important and often neglected aspect of the management of schizophrenia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bland RC, Newman SC, Orn H. Schizophrenia: lifetime co-morbidity in a community sample. Acta Psychiatr Scand. 1987;75(4):383–91.

    Article  CAS  PubMed  Google Scholar 

  2. Boyd JH. Use of mental health services for the treatment of panic disorder. Am J Psychiatry. 1986;143(12):1569–74.

    Article  CAS  PubMed  Google Scholar 

  3. Goodwin R, Lyons JS, McNally RJ. Panic attacks in schizophrenia. Schizophr Res. 2002;58(2–3):213–20.

    Article  PubMed  Google Scholar 

  4. Braga RJ, Reynolds GP, Siris SG. Anxiety comorbidity in schizophrenia. Psychiatry Res. 2013;210(1):1–7.

    Article  PubMed  Google Scholar 

  5. Fenton WS, McGlashan TH. The prognostic significance of obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry. 1986;143(4):437–41.

    Article  CAS  PubMed  Google Scholar 

  6. Wilk JE, West JC, Narrow WE, Marcus S, Rubio-Stipec M, Rae DS, et al. Comorbidity patterns in routine psychiatric practice: is there evidence of underdetection and underdiagnosis? Compr Psychiatry. 2006;47(4):258–64.

    Article  PubMed  Google Scholar 

  7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Association; 2013.

    Google Scholar 

  8. Achim AM, Maziade M, Raymond E, Olivier D, Merette C, Roy MA. How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull. 2011;37(4):811–21.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Somers JM, Goldner EM, Waraich P, Hsu L. Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. Can J Psychiatry Rev Can Psychiatr. 2006;51(2):100–13.

    Google Scholar 

  10. Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. Schizophr Bull. 2009;35(2):383–402.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Michail M, Birchwood M. Social anxiety disorder in first-episode psychosis: incidence, phenomenology and relationship with paranoia. Br J Psychiatry J Ment Sci. 2009;195(3):234–41.

    Article  Google Scholar 

  12. World Health Organization. The ICD-10 classification of mental and behavioral disorders. Geneva: Diagnostic Criteria for Research; 1992.

    Google Scholar 

  13. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute; 2002.

  14. Seedat S, Fritelli V, Oosthuizen P, Emsley RA, Stein DJ. Measuring anxiety in patients with schizophrenia. J Nerv Ment Dis. 2007;195(4):320–4.

    Article  PubMed  Google Scholar 

  15. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006–11.

    Article  CAS  PubMed  Google Scholar 

  16. Bosanac P, Mancuso S, Castle D. Anxiety symptoms in psychotic disorders. Clin Schizophr Relat Psychoses. 2013;18:1–22.

    Article  Google Scholar 

  17. Emsley RA, Oosthuizen PP, Joubert AF, Roberts MC, Stein DJ. Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder. J Clin Psychiatry. 1999;60(11):747–51.

    Article  CAS  PubMed  Google Scholar 

  18. Faragian S, Fuchs C, Pashinian A, Weizman R, Weizman A, Poyurovsky M. Age-of-onset of schizophrenic and obsessive-compulsive symptoms in patients with schizo-obsessive disorder. Psychiatry Res. 2012;197(1–2):19–22.

    Article  PubMed  Google Scholar 

  19. Poyurovsky M, Faragian S, Shabeta A, Kosov A. Comparison of clinical characteristics, co-morbidity and pharmacotherapy in adolescent schizophrenia patients with and without obsessive-compulsive disorder. Psychiatry Res. 2008;159(1–2):133–9.

    Article  CAS  PubMed  Google Scholar 

  20. Lim J, Rekhi G, Rapisarda A, Lam M, Kraus M, Keefe RS, et al. Impact of psychiatric comorbidity in individuals at Ultra High Risk of psychosis—findings from the Longitudinal Youth at Risk Study (LYRIKS). Schizophr Res. 2015;164(1–3):8–14.

    Article  PubMed  Google Scholar 

  21. Johnstone EC, Ebmeier KP, Miller P, Owens DG, Lawrie SM. Predicting schizophrenia: findings from the Edinburgh High-Risk Study. Br J Psychiatry J Ment Sci. 2005;186:18–25.

    Article  Google Scholar 

  22. Tien AY, Eaton WW. Psychopathologic precursors and sociodemographic risk factors for the schizophrenia syndrome. Arch Gen Psychiatry. 1992;49(1):37–46.

    Article  CAS  PubMed  Google Scholar 

  23. Cederlof M, Lichtenstein P, Larsson H, Boman M, Ruck C, Landen M, et al. Obsessive-compulsive disorder, psychosis, and bipolarity: a longitudinal cohort and multigenerational family study. Schizophr Bull. 2015;41(5):1076–83.

    Article  PubMed  Google Scholar 

  24. Meier SM, Petersen L, Pedersen MG, Arendt MC, Nielsen PR, Mattheisen M, et al. Obsessive-compulsive disorder as a risk factor for schizophrenia: a nationwide study. JAMA Psychiatry. 2014;71(11):1215–21.

    Article  PubMed  Google Scholar 

  25. Owens DG, Miller P, Lawrie SM, Johnstone EC. Pathogenesis of schizophrenia: a psychopathological perspective. Br J Psychiatry J Ment Sci. 2005;186:386–93.

    Article  Google Scholar 

  26. Veras AB, Souza TG, Ricci TG, de Souza CP, Moryiama MC, Nardi AE, et al. Paranoid delusional disorder follows social anxiety disorder in a long-term case series: evolutionary perspective. J Nerv Ment Dis. 2015;203(6):477–9.

    Article  PubMed  Google Scholar 

  27. Fusar-Poli P, Nelson B, Valmaggia L, Yung AR, McGuire PK. Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis. Schizophr Bull. 2014;40(1):120–31.

    Article  PubMed Central  PubMed  Google Scholar 

  28. Calhoun PS, Bosworth HB, Stechuchak KA, Strauss J, Butterfield MI. The impact of posttraumatic stress disorder on quality of life and health service utilization among veterans who have schizophrenia. J Trauma Stress. 2006;19(3):393–7.

    Article  PubMed  Google Scholar 

  29. Mueser KT, Salyers MP, Rosenberg SD, Goodman LA, Essock SM, Osher FC, et al. Interpersonal trauma and posttraumatic stress disorder in patients with severe mental illness: demographic, clinical, and health correlates. Schizophr Bull. 2004;30(1):45–57.

    Article  PubMed  Google Scholar 

  30. Birgenheir DG, Ganoczy D, Bowersox NW. Service utilization among veterans with schizophrenia and a comorbid anxiety disorder. Psychiatr Serv. 2014;65(11):1354–9.

    Article  PubMed  Google Scholar 

  31. Braga RJ, Petrides G, Figueira I. Anxiety disorders in schizophrenia. Compr Psychiatry. 2004;45(6):460–8.

    Article  PubMed  Google Scholar 

  32. Huppert JD, Weiss KA, Lim R, Pratt S, Smith TE. Quality of life in schizophrenia: contributions of anxiety and depression. Schizophr Res. 2001;51(2–3):171–80.

    Article  CAS  PubMed  Google Scholar 

  33. Lowengrub KM, Stryjer R, Birger M, Iancu I. Social anxiety disorder comorbid with schizophrenia: the importance of screening for this under recognized and under treated condition. Isr J Psychiatry Relat Sci. 2015;52(1):40–5.

    PubMed  Google Scholar 

  34. Ulas H, Polat S, Akdede BB, Alptekin K. Impact of panic attacks on quality of life among patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(7):1300–5.

    Article  PubMed  Google Scholar 

  35. de Haan L, Sterk B, van der Valk R. Presence of obsessive compulsive symptoms in first-episode schizophrenia or related disorders is associated with subjective well-being and quality of life. Early Interv Psychiatry. 2013;7(3):285–90.

    Article  PubMed  Google Scholar 

  36. Kim SW, Jeong BO, Kim JM, Shin IS, Hwang MY, Paul Amminger G, et al. Associations of obsessive-compulsive symptoms with clinical and neurocognitive features in schizophrenia according to stage of illness. Psychiatry Res. 2015;226(1):368–75.

    Article  PubMed  Google Scholar 

  37. Devi S, Rao NP, Badamath S, Chandrashekhar CR, Reddy YCJ. Prevalence and clinical correlates of obsessive-compulsive disorder in schizophrenia. Compr Psychiatry. 2015;56:141–8.

    Article  PubMed  Google Scholar 

  38. de Haan L, Sterk B, Wouters L, Linszen DH. The 5-year course of obsessive-compulsive symptoms and obsessive-compulsive disorder in first-episode schizophrenia and related disorders. Schizophr Bull. 2013;39(1):151–60.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Nyhuis AW, Faries DE, Ascher-Svanum H, Stauffer VL, Kinon BJ. Predictors of switching antipsychotic medications in the treatment of schizophrenia. BMC Psychiatry. 2010;10:75.

    Article  PubMed Central  PubMed  Google Scholar 

  40. Tibbo P, Swainson J, Chue P, LeMelledo JM. Prevalence and relationship to delusions and hallucinations of anxiety disorders in schizophrenia. Depress Anxiety. 2003;17(2):65–72.

    Article  PubMed  Google Scholar 

  41. Lysaker PH, Ringer JM, Davis LW. Associations of social anxiety and self-esteem across six months for persons living with schizophrenia spectrum disorders. Psychiatr Rehabil J. 2008;32(2):132–4.

    Article  PubMed  Google Scholar 

  42. Naidu K, van Staden WC, van der Linde M. Severity of psychotic episodes in predicting concurrent depressive and anxiety features in acute phase schizophrenia. BMC Psychiatry. 2014;14:166.

    Article  PubMed Central  PubMed  Google Scholar 

  43. Dombrowski M, McCleery A, Gregory SW Jr, Docherty NM. Stress reactivity of emotional and verbal speech content in schizophrenia. J Nerv Ment Dis. 2014;202(8):608–12.

    Article  PubMed  Google Scholar 

  44. Lysaker PH, Marks KA, Picone JB, Rollins AL, Fastenau PS, Bond GR. Obsessive and compulsive symptoms in schizophrenia: clinical and neurocognitive correlates. J Nerv Ment Dis. 2000;188(2):78–83.

    Article  CAS  PubMed  Google Scholar 

  45. Poyurovsky M, Kriss V, Weisman G, Faragian S, Kurs R, Schneidman M, et al. Comparison of clinical characteristics and comorbidity in schizophrenia patients with and without obsessive-compulsive disorder: schizophrenic and OC symptoms in schizophrenia. J Clin Psychiatry. 2003;64(11):1300–7.

    Article  PubMed  Google Scholar 

  46. Cunill R, Castells X, Simeon D. Relationships between obsessive-compulsive symptomatology and severity of psychosis in schizophrenia: a systematic review and meta-analysis. J Clin Psychiatry. 2009;70(1):70–82.

    Article  PubMed  Google Scholar 

  47. Sutliff S, Roy MA, Achim AM. Social anxiety disorder in recent onset schizophrenia spectrum disorders: the relation with symptomatology, anxiety, and social rank. Psychiatry Res. 2015;227(1):39–45.

    Article  PubMed  Google Scholar 

  48. Hwang MY, Morgan JE, Losconzcy MF. Clinical and neuropsychological profiles of obsessive-compulsive schizophrenia: a pilot study. J Neuropsychiatry Clin Neurosci. 2000;12(1):91–4.

    Article  CAS  PubMed  Google Scholar 

  49. Jovanovic N, Podlesek A, Medved V, Grubisin J, Mihaljevic-Peles A, Goran T, et al. Association between psychopathology and suicidal behavior in schizophrenia. A cross-sectional study of 509 participants. Crisis. 2013;34(6):374–81.

    Article  PubMed  Google Scholar 

  50. Tsai J, Rosenheck RA. Psychiatric comorbidity among adults with schizophrenia: a latent class analysis. Psychiatry Res. 2013;210(1):16–20.

    Article  PubMed Central  PubMed  Google Scholar 

  51. Poyurovsky M, Faragian S, Kleinman-Balush V, Pashinian A, Kurs R, Fuchs C. Awareness of illness and insight into obsessive-compulsive symptoms in schizophrenia patients with obsessive-compulsive disorder. J Nerv Ment Dis. 2007;195(9):765–8.

    Article  PubMed  Google Scholar 

  52. van Nierop M, Viechtbauer W, Gunther N, van Zelst C, de Graaf R, Ten Have M, et al. Childhood trauma is associated with a specific admixture of affective, anxiety, and psychosis symptoms cutting across traditional diagnostic boundaries. Psychol Med. 2015;45(6):1277–88.

    Article  PubMed  Google Scholar 

  53. Cunill R, Huerta-Ramos E, Castells X. The effect of obsessive-compulsive symptomatology on executive functions in schizophrenia: a systematic review and meta-analysis. Psychiatry Res. 2013;210(1):21–8.

    Article  PubMed  Google Scholar 

  54. Schirmbeck F, Rausch F, Englisch S, Eifler S, Esslinger C, Meyer-Lindenberg A, et al. Stable cognitive deficits in schizophrenia patients with comorbid obsessive-compulsive symptoms: a 12-month longitudinal study. Schizophr Bull. 2013;39(6):1261–71.

    Article  PubMed Central  PubMed  Google Scholar 

  55. Halasz I, Levy-Gigi E, Kelemen O, Benedek G, Keri S. Neuropsychological functions and visual contrast sensitivity in schizophrenia: the potential impact of comorbid posttraumatic stress disorder (PTSD). Front Psychol. 2013;4:136.

    Article  PubMed Central  PubMed  Google Scholar 

  56. Krueger RF, Markon KE. Reinterpreting comorbidity: a model-based approach to understanding and classifying psychopathology. Annu Rev Clin Psychol. 2006;2:111–33.

    Article  PubMed Central  PubMed  Google Scholar 

  57. Ofrat S, Krueger RF. How research on the meta-structure of psychopathology aids in understanding biological correlates of mood and anxiety disorders. Biol Mood Anxiety Disord. 2012;2(1):13.

    Article  PubMed Central  PubMed  Google Scholar 

  58. Carragher N, Krueger RF, Eaton NR, Slade T. Disorders without borders: current and future directions in the meta-structure of mental disorders. Soc Psychiatry Psychiatr Epidemiol. 2015;50(3):339–50.

    Article  PubMed  Google Scholar 

  59. Seedat F, Roos JL, Pretorius HW, Karayiorgou M, Nel B. Prevalence and clinical characteristics of obsessive-compulsive disorder and obsessive compulsive symptoms in Afrikaner schizophrenia and schizoaffective disorder patients. Afr J Psychiatry (Johannesbg). 2007;10(4):219–24.

    CAS  Google Scholar 

  60. Dekker N, Swets M. Substance use in a large sample of patients with schizophrenia or related disorders and co-morbid obsessive-compulsive symptoms. Aust N Z J Psychiatry. 2013;47(9):868–74.

    Article  PubMed  Google Scholar 

  61. Goodwin RD, Amador XF, Malaspina D, Yale SA, Goetz RR, Gorman JM. Anxiety and substance use comorbidity among inpatients with schizophrenia. Schizophr Res. 2003;61(1):89–95.

    Article  PubMed  Google Scholar 

  62. Scheller-Gilkey G, Thomas SM, Woolwine BJ, Miller AH. Increased early life stress and depressive symptoms in patients with comorbid substance abuse and schizophrenia. Schizophr Bull. 2002;28(2):223–31.

    Article  PubMed  Google Scholar 

  63. Aleman A, Kahn RS. Strange feelings: do amygdala abnormalities dysregulate the emotional brain in schizophrenia? Prog Neurobiol. 2005;77(5):283–98.

    PubMed  Google Scholar 

  64. Kring AM, Elis O. Emotion deficits in people with schizophrenia. Annu Rev Clin Psychol. 2013;9:409–33.

    Article  PubMed  Google Scholar 

  65. Roux P, Christophe A, Passerieux C. The emotional paradox: dissociation between explicit and implicit processing of emotional prosody in schizophrenia. Neuropsychologia. 2010;48(12):3642–9.

    Article  CAS  PubMed  Google Scholar 

  66. Li H, Chan RC, McAlonan GM, Gong QY. Facial emotion processing in schizophrenia: a meta-analysis of functional neuroimaging data. Schizophr Bull. 2010;36(5):1029–39.

    Article  PubMed Central  PubMed  Google Scholar 

  67. Sugranyes G, Kyriakopoulos M, Corrigall R, Taylor E, Frangou S. Autism spectrum disorders and schizophrenia: meta-analysis of the neural correlates of social cognition. PLoS One. 2011;6(10):e25322.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  68. van ‘t Wout M, Aleman A, Kessels RP, Cahn W, de Haan EH, Kahn RS. Exploring the nature of facial affect processing deficits in schizophrenia. Psychiatry Res. 2007;150(3):227–35.

    Article  Google Scholar 

  69. Kring AM, Neale JM. Do schizophrenic patients show a disjunctive relationship among expressive, experiential, and psychophysiological components of emotion? J Abnorm Psychol. 1996;105(2):249–57.

    Article  CAS  PubMed  Google Scholar 

  70. Williams LM, Das P, Harris AW, Liddell BB, Brammer MJ, Olivieri G, et al. Dysregulation of arousal and amygdala-prefrontal systems in paranoid schizophrenia. Am J Psychiatry. 2004;161(3):480–9.

    Article  PubMed  Google Scholar 

  71. Yamasue H, Fukui T, Fukuda R, Yamada H, Yamasaki S, Kuroki N, et al. 1H-MR spectroscopy and gray matter volume of the anterior cingulate cortex in schizophrenia. NeuroReport. 2002;13(16):2133–7.

    Article  CAS  PubMed  Google Scholar 

  72. Gur RE, Turetsky BI, Cowell PE, Finkelman C, Maany V, Grossman RI, et al. Temporolimbic volume reductions in schizophrenia. Arch Gen Psychiatry. 2000;57(8):769–75.

    Article  CAS  PubMed  Google Scholar 

  73. Sun MM, Yang LM, Wang Y, Feng X, Cui KY, Liu LF, et al. BDNF Val66Met polymorphism and anxiety/depression symptoms in schizophrenia in a Chinese Han population. Psychiatr Genet. 2013;23(3):124–9.

    Article  CAS  PubMed  Google Scholar 

  74. Xu K, Ernst M, Goldman D. Imaging genomics applied to anxiety, stress response, and resiliency. Neuroinformatics. 2006;4(1):51–64.

    Article  PubMed  Google Scholar 

  75. Li W, Yang Y, Lin J, Wang S, Zhao J, Yang G, et al. Association of serotonin transporter gene (SLC6A4) polymorphisms with schizophrenia susceptibility and symptoms in a Chinese-Han population. Prog Neuropsychopharmacol Biol Psychiatry. 2013;1(44):290–5.

    Article  CAS  Google Scholar 

  76. Celada P, Bortolozzi A, Artigas F. Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs. 2013;27(9):703–16.

    Article  CAS  PubMed  Google Scholar 

  77. Garay RP, Samalin L, Hameg A, Llorca PM. Investigational drugs for anxiety in patients with schizophrenia. Expert Opin Investig Drugs. 2015;24(4):507–17.

    Article  CAS  PubMed  Google Scholar 

  78. Sirota P, Epstein B, Benatov R, Sousnostzky M, Kindler S. An open study of buspirone augmentation of neuroleptics in patients with schizophrenia. J Clin Psychopharmacol. 2001;21(4):454–5.

    Article  CAS  PubMed  Google Scholar 

  79. Englisch S, Esser A, Enning F, Hohmann S, Schanz H, Zink M. Augmentation with pregabalin in schizophrenia. J Clin Psychopharmacol. 2010;30(4):437–40.

    Article  CAS  PubMed  Google Scholar 

  80. Miodownik C, Maayan R, Ratner Y, Lerner V, Pintov L, Mar M, et al. Serum levels of brain-derived neurotrophic factor and cortisol to sulfate of dehydroepiandrosterone molar ratio associated with clinical response to l-theanine as augmentation of antipsychotic therapy in schizophrenia and schizoaffective disorder patients. Clin Neuropharmacol. 2011;34(4):155–60.

    Article  CAS  PubMed  Google Scholar 

  81. Ritsner MS, Miodownik C, Ratner Y, Shleifer T, Mar M, Pintov L, et al. L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study. J Clin Psychiatry. 2011;72(1):34–42.

    Article  CAS  PubMed  Google Scholar 

  82. Bakermans-Kranenburg MJ, van I Jzendoorn MH. Sniffing around oxytocin: review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapy. Transl Psychiatry. 2013;3:e258.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  83. Shin NY, Park HY, Jung WH, Park JW, Yun JY, Jang JH, et al. Effects of oxytocin on neural response to facial expressions in patients with schizophrenia. Neuropsychopharmacology. 2015;40(8):1919–27.

    Article  CAS  PubMed  Google Scholar 

  84. Zhornitsky S, Potvin S. Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals (Basel). 2012;5(5):529–52.

    Article  CAS  Google Scholar 

  85. Cedro A, Kokoszka A, Popiel A, Narkiewicz-Jodko W. Alexithymia in schizophrenia: an exploratory study. Psychol Rep. 2001;89(1):95–8.

    Article  CAS  PubMed  Google Scholar 

  86. Fogley R, Warman D, Lysaker PH. Alexithymia in schizophrenia: associations with neurocognition and emotional distress. Psychiatry Res. 2014;218(1–2):1–6.

    Article  PubMed  Google Scholar 

  87. van ‘t Wout M, Aleman A, Bermond B, Kahn RS. No words for feelings: alexithymia in schizophrenia patients and first-degree relatives. Compr Psychiatry. 2007;48(1):27–33.

    Article  Google Scholar 

  88. Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry. 1987;22:141–73.

    Article  CAS  PubMed  Google Scholar 

  89. Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE, Woods SW, et al. Multicenter collaborative panic disorder severity scale. Am J Psychiatry. 1997;154(11):1571–5.

    Article  CAS  PubMed  Google Scholar 

  90. Stein DJ. Generalized anxiety disorder: rethinking diagnosis and rating. CNS Spectr. 2005;10(12):930–4.

    PubMed  Google Scholar 

  91. Stopa L, Denton R, Wingfield M, Taylor KN. The fear of others: a qualitative analysis of interpersonal threat in social phobia and paranoia. Behav Cogn Psychother. 2013;41(2):188–209.

    Article  PubMed  Google Scholar 

  92. Poyurovsky M, Koran LM. Obsessive-compulsive disorder (OCD) with schizotypy vs. schizophrenia with OCD: diagnostic dilemmas and therapeutic implications. J Psychiatr Res. 2005;39(4):399–408.

    Article  CAS  PubMed  Google Scholar 

  93. Poyurovsky M, Weizman A, Weizman R. Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment. CNS Drugs. 2004;18(14):989–1010.

    Article  CAS  PubMed  Google Scholar 

  94. Poyurovsky M, Zohar J, Glick I, Koran LM, Weizman R, Tandon R, et al. Obsessive-compulsive symptoms in schizophrenia: implications for future psychiatric classifications. Compr Psychiatry. 2012;53(5):480–3.

    Article  PubMed  Google Scholar 

  95. Frias A, Palma C, Farriols N, Salvador A, Bonet J, Bernaldez I. Psychopathology and quality of life among patients with comorbidity between schizophrenia spectrum disorder and obsessive-compulsive disorder: no evidence for a “schizo-obsessive” subtype. Compr Psychiatry. 2014;55(5):1165–73.

    Article  PubMed  Google Scholar 

  96. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 2000.

    Google Scholar 

  97. Bendall S, Hulbert CA, Alvarez-Jimenez M, Allott K, McGorry PD, Jackson HJ. Testing a model of the relationship between childhood sexual abuse and psychosis in a first-episode psychosis group: the role of hallucinations and delusions, posttraumatic intrusions, and selective attention. J Nerv Ment Dis. 2013;201(11):941–7.

    Article  PubMed  Google Scholar 

  98. Varese F, Barkus E, Bentall RP. Dissociation mediates the relationship between childhood trauma and hallucination-proneness. Psychol Med. 2012;42(5):1025–36.

    Article  CAS  PubMed  Google Scholar 

  99. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672–6.

    Article  CAS  PubMed  Google Scholar 

  100. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50–5.

    Article  CAS  PubMed  Google Scholar 

  101. Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, et al. The development of a Clinician-Administered PTSD Scale. J Trauma Stress. 1995;8(1):75–90.

    Article  CAS  PubMed  Google Scholar 

  102. PROMIS-Emotional Distress-Anxiety-Short-form. Level 2-anxiety-adult. 2008–2012 ed. PROMIS Health Organization and PROMIS Cooperative Group; 2008–2012.

  103. American Psychiatric Association. Clinician-rated dimensions of psychosis symptom severity scale. 2013 [cited 2015 28 May 2015]. http://www.psychiatry.org/dsm5.

  104. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–76.

    Article  CAS  PubMed  Google Scholar 

  105. Guy W. ECDEU assessment manual for psychopharmacology-revised (DHHS Publ No ADM 91-338). Rockville: US Department of Health and Human Services; 1976. p. 534–7.

    Google Scholar 

  106. Llorca PM, Lancon C, Blanc O, de Chazeron I, Samalin L, Caci H, et al. A composite scale applied to evaluate anxiety in schizophrenic patients (SAES). Eur Arch Psychiatry Clin Neurosci. 2014;264(2):171–8.

    Article  PubMed  Google Scholar 

  107. Naeem F, Kingdon D, Turkington D. Cognitive behaviour therapy for schizophrenia: relationship between anxiety symptoms and therapy. Psychol Psychother. 2006;79(Pt 2):153–64.

    Article  PubMed  Google Scholar 

  108. Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36(1):94–103.

    Article  PubMed Central  PubMed  Google Scholar 

  109. Gao K, Muzina D, Gajwani P, Calabrese JR. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry. 2006;67(9):1327–40.

    Article  CAS  PubMed  Google Scholar 

  110. Mendels J, Krajewski TF, Huffer V, Taylor RJ, Secunda S, Schless A, et al. Effective short-term treatment of generalized anxiety disorder with trifluoperazine. J Clin Psychiatry. 1986;47(4):170–4.

    CAS  PubMed  Google Scholar 

  111. Blin O, Azorin JM, Bouhours P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol. 1996;16(1):38–44.

    Article  CAS  PubMed  Google Scholar 

  112. Vulink NC, Figee M, Denys D. Review of atypical antipsychotics in anxiety. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2011;21(6):429–49.

    Article  CAS  Google Scholar 

  113. Buckley PF. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials. Curr Med Res Opin. 2004;20(9):1357–63.

    Article  CAS  PubMed  Google Scholar 

  114. Depping AM, Komossa K, Kissling W, Leucht S. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev. 2010;12:CD008120.

  115. Kasper S. Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia. Depress Anxiety. 2004;20(1):44–7.

    Article  CAS  PubMed  Google Scholar 

  116. Zhornitsky S, Potvin S, Moteshafi H, Dubreucq S, Rompre PP, Stip E. Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials. Int Clin Psychopharmacol. 2011;26(4):183–92.

    Article  PubMed  Google Scholar 

  117. Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2013;11:CD006625.

  118. Kasper S, Montagnani G, Trespi G, Di Fiorino M. Treatment of depressive symptoms in patients with schizophrenia: a randomized, open-label, parallel-group, flexible-dose subgroup analysis of patients treated with extended-release quetiapine fumarate or risperidone. Int Clin Psychopharmacol. 2015;30(1):14–22.

    Article  PubMed  Google Scholar 

  119. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71–93.

    Article  PubMed Central  PubMed  Google Scholar 

  120. Glick ID, Poyurovsky M, Ivanova O, Koran LM. Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients. J Clin Psychiatry. 2008;69(12):1856–9.

    Article  CAS  PubMed  Google Scholar 

  121. Veale D, Miles S, Smallcombe N, Ghezai H, Goldacre B, Hodsoll J. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. BMC Psychiatry. 2014;14(1):317.

    Article  PubMed Central  PubMed  Google Scholar 

  122. Ducasse D, Boyer L, Michel P, Loundou A, Macgregor A, Micoulaud-Franchi JA, et al. D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysis. Psychopharmacology. 2014;231(18):3765–70.

    Article  CAS  PubMed  Google Scholar 

  123. Stern RG, Petti TA, Bopp K, Tobia A. Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: an open-label cross-taper study. J Clin Psychopharmacol. 2009;29(3):206–9.

    Article  CAS  PubMed  Google Scholar 

  124. Tollefson GD, Sanger TM. Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy? Schizophr Res. 1999;1(35 Suppl):S13–21.

    Article  Google Scholar 

  125. Berman I, Sapers BL, Chang HH, Losonczy MF, Schmildler J, Green AI. Treatment of obsessive-compulsive symptoms in schizophrenic patients with clomipramine. J Clin Psychopharmacol. 1995;15(3):206–10.

    Article  CAS  PubMed  Google Scholar 

  126. Reznik I, Sirota P. Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics. J Clin Psychopharmacol. 2000;20(4):410–6.

    Article  CAS  PubMed  Google Scholar 

  127. Mulholland C, Lynch G, King DJ, Cooper SJ. A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia. J Psychopharmacol. 2003;17(1):107–12.

    Article  CAS  PubMed  Google Scholar 

  128. Pallanti S, Quercioli L, Rossi A, Pazzagli A. The emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation. J Clin Psychiatry. 1999;60(12):819–23.

    Article  CAS  PubMed  Google Scholar 

  129. Agarwal V, Agarwal KM. Treatment of obsessive compulsive symptoms in schizophrenia with fluoxetine. Indian J Psychiatry. 2000;42(3):291–4.

    PubMed Central  CAS  PubMed  Google Scholar 

  130. Stryjer R, Dambinsky Y, Timinsky I, Green T, Kotler M, Weizman A, et al. Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study. Int Clin Psychopharmacol. 2013;28(2):96–8.

    Article  PubMed  Google Scholar 

  131. Reznik I, Sirota P. An open study of fluvoxamine augmentation of neuroleptics in schizophrenia with obsessive and compulsive symptoms. Clin Neuropharmacol. 2000;23(3):157–60.

    Article  CAS  PubMed  Google Scholar 

  132. Poyurovsky M, Isakov V, Hromnikov S, Modai I, Rauchberger B, Schneidman M, et al. Fluvoxamine treatment of obsessive-compulsive symptoms in schizophrenic patients: an add-on open study. Int Clin Psychopharmacol. 1999;14(2):95–100.

    Article  CAS  PubMed  Google Scholar 

  133. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 3: update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry. 2015;16(3):142–70.

    Article  Google Scholar 

  134. Kishi T, Iwata N. Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia. Int J Neuropsychopharmacol Off Sci J Coll Int Neuropsychopharmacol. 2014;17(2):343–54.

    CAS  Google Scholar 

  135. Rummel C, Kissling W, Leucht S. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev. 2006;3:CD005581.

  136. Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012;16(2):77–84.

    Article  CAS  PubMed  Google Scholar 

  137. Spina E, Santoro V, D’Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther. 2008;30(7):1206–27.

    Article  CAS  PubMed  Google Scholar 

  138. Mao YM, Zhang MD. Augmentation with antidepressants in schizophrenia treatment: benefit or risk. Neuropsychiatr Dis Treat. 2015;11:701–13.

    PubMed Central  PubMed  Google Scholar 

  139. Beach SR, Kostis WJ, Celano CM, Januzzi JL, Ruskin JN, Noseworthy PA, et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry. 2014;75(5):e441–9.

    Article  PubMed  Google Scholar 

  140. Funk KA, Bostwick JR. A comparison of the risk of QT prolongation among SSRIs. Ann Pharmacother. 2013;47(10):1330–41.

    Article  CAS  PubMed  Google Scholar 

  141. Glassman AH, O’Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288(6):701–9.

    Article  CAS  PubMed  Google Scholar 

  142. Mavrides N, Nemeroff CB. Treatment of affective disorders in cardiac disease. Dialogues Clin Neurosci. 2015;17(2):127–40.

    PubMed Central  PubMed  Google Scholar 

  143. Sala M, Vicentini A, Brambilla P, Montomoli C, Jogia JR, Caverzasi E, et al. QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry. 2005;4(1):1.

    Article  PubMed Central  PubMed  Google Scholar 

  144. Croom KF, Perry CM, Plosker GL. Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs. 2009;23(5):427–52.

    Article  CAS  PubMed  Google Scholar 

  145. Poyurovsky M, Pashinian A, Weizman R, Fuchs C, Weizman A. Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial. Biol Psychiatry. 2006;59(11):1071–7.

    Article  CAS  PubMed  Google Scholar 

  146. Frampton JE. Pregabalin: a review of its use in adults with generalized anxiety disorder. CNS Drugs. 2014;28(9):835–54.

    Article  CAS  PubMed  Google Scholar 

  147. Holzschneider K, Mulert C. Neuroimaging in anxiety disorders. Dialogues Clin Neurosci. 2011;13(4):453–61.

    PubMed Central  PubMed  Google Scholar 

  148. Papazisis G, Tzachanis D. Pregabalin’s abuse potential: a mini review focusing on the pharmacological profile. Int J Clin Pharmacol Ther. 2014;52(8):709–16.

    Article  CAS  PubMed  Google Scholar 

  149. Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs. 2014;28(6):491–6.

    Article  CAS  PubMed  Google Scholar 

  150. Englisch S, Alm B, Meyer-Lindenberg A, Zink M. Pregabalin-associated increase of clozapine serum levels. J Clin Psychopharmacol. 2012;32(1):127.

    Article  PubMed  Google Scholar 

  151. Kishi T, Meltzer HY, Iwata N. Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis. Int J Neuropsychopharmacol Off Sci J Coll Int Neuropsychopharmacol. 2013;16(6):1259–66.

    CAS  Google Scholar 

  152. Dold M, Li C, Gillies D, Leucht S. Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2013;23(9):1023–33.

    Article  CAS  Google Scholar 

  153. Scheltema BAA, Swets M, Machielsen M, Korver N. Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients. J Clin Psychiatry. 2012;73(11):1395–402.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Mental Health, University of Cape Town, Education Centre, Valkenberg Hospital, Private Bag X1, Observatory, Cape Town, 7935, South Africa

    Henk Temmingh

  2. Department of Psychiatry and Mental Health, MRC Unit on Anxiety and Stress Disorders, University of Cape Town, Groote Schuur Hospital (J-2), Anzio Rd, Observatory, Cape Town, 7925, South Africa

    Dan J. Stein

Authors
  1. Henk Temmingh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dan J. Stein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Henk Temmingh.

Ethics declarations

Conflict of interest

In the past 3 years, Henk Temmingh has received a speaker’s honorarium from Pharma-dynamics. In the past 3 years, Dan Stein has received research grants and/or consultancy honoraria from AMBRF, Biocodex, Cipla, Lundbeck, Novartis, Sun, Servier, and the National Responsible Gambling Foundation.

Funding

No sources of funding were used in the preparation of this manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Temmingh, H., Stein, D.J. Anxiety in Patients with Schizophrenia: Epidemiology and Management. CNS Drugs 29, 819–832 (2015). https://doi.org/10.1007/s40263-015-0282-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-015-0282-7

Keywords

Search

Navigation